The goal of the main clinical research study is to learn if treatment with a chimeric antigen receptor (CAR) T-cell therapy called lisocabtagene maraleucel (liso-cel) can help to prevent recurrence of large B-cell cell lymphoma in patients who have achieved complete response (CR) after standard first-line therapy but have tested positive for lymphoma DNA. CAR T therapy is a type of treatment that uses your own immune cells to fight your cancer. The safety of this treatment will also be studied.
R-CHOP (cyclophosphamide, doxorubicin, vincristine sulfate, and prednisone)
DA-EPOCH-R
Polatuzumab-R-CHP 8. Achieved complete metabolic response by Lugano criteria4 at the end of treatment response evaluation after first line treatment
Absolute neutrophil count (ANC) ≥1.0 × 109 /L*
Having radiologically confirmed relapsed/refractory disease.
Have not recovered from non-hematological AEs due to prior first line therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
Known central nervous system lymphoma or leptomeningeal disease.
Adequately treated localized non-melanoma skin cancer without evidence of disease.
Single group
Leukapheresis
Procedure/SurgeryGiven by infusion
Lymphodepleting Chemotherapy
DrugGiven by IV
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Click on the lead sponsor to view all of their trials.
